Lurbinectedin in FET-Fused Tumors

The purpose of this study is to find out if a drug called lurbinectedin (the "study drug") is safe and effective at treating people with recurrent or relapsed solid tumors, including Ewing sarcoma.

Trial Details

NCT ID
NCT05918640
Phase
PHASE1 / PHASE2
Sponsor
Children's Hospital of Philadelphia
Status
RECRUITING
Cancer Type
Osteosarcoma Sarcoma
Interventions
  • Lurbinectedin
Locations (sample)
  • Los Angeles, California, United States|34.05223,-118.24368
  • Iowa City, Iowa, United States|41.66113,-91.53017
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • Ann Arbor, Michigan, United States|42.27756,-83.74088
  • New York, New York, United States|40.71427,-74.00597

Key Eligibility Criteria

  • Age ≥ 10 years.
  • Phase 1: Histological confirmed diagnosis of recurrent or relapsed solid tumor failing primary therapy. Patients must have a known FET fusion (fusi…
  • Phase 2: Histologically confirmed diagnosis of recurrent or relapsed Ewing sarcoma failing primary therapy with confirmation of EWS-FLI1 fusion and…
  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 (age \>16 years) or Lansky of at least 70 (age \<16 years).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Osteosarcoma Sarcoma Trials on Trialify →